Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Liabilities and Shareholders Equity (2022 - 2025)

Century Therapeutics (IPSC) has disclosed Liabilities and Shareholders Equity for 4 consecutive years, with $223.7 million as the latest value for Q4 2025.

  • Quarterly Liabilities and Shareholders Equity fell 36.67% to $223.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.1 billion through Dec 2025, down 29.07% year-over-year, with the annual reading at $223.7 million for FY2025, 36.67% down from the prior year.
  • Liabilities and Shareholders Equity for Q4 2025 was $223.7 million at Century Therapeutics, down from $244.7 million in the prior quarter.
  • The five-year high for Liabilities and Shareholders Equity was $550.3 million in Q1 2022, with the low at $223.7 million in Q4 2025.
  • Average Liabilities and Shareholders Equity over 4 years is $393.0 million, with a median of $393.1 million recorded in 2023.
  • The sharpest move saw Liabilities and Shareholders Equity fell 0.17% in 2024, then tumbled 37.03% in 2025.
  • Over 4 years, Liabilities and Shareholders Equity stood at $486.5 million in 2022, then dropped by 25.87% to $360.7 million in 2023, then decreased by 2.07% to $353.2 million in 2024, then crashed by 36.67% to $223.7 million in 2025.
  • According to Business Quant data, Liabilities and Shareholders Equity over the past three periods came in at $223.7 million, $244.7 million, and $284.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.